SecSonar.com

Evotec SE (EVO)

Evotec SE at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Evotec SE (EVO) is a Drug Manufacturers - Specialty & Generic company based in DE with a market capitalization of $1.1B. Revenue declined 5.0% year-over-year and free cash flow was negative at -$78.7M. This page tracks EVO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DE · 4.77K employees · IPO Feb 5, 2004

Valuation

Valuation & price

$2.90 · as of May 26, 2026 · -31.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.26$3.32$2.38Jul 25Dec 25Jul 26Jul 7, 25$4.18Jul 9, 25$4.15Jul 11, 25$4.07Jul 15, 25$4.20Jul 17, 25$4.24Jul 21, 25$3.69Jul 23, 25$3.82Jul 25, 25$4.26Jul 29, 25$4.24Jul 31, 25$3.98Aug 4, 25$3.88Aug 6, 25$3.75Aug 11, 25$3.81Aug 13, 25$3.81Aug 15, 25$3.76Aug 19, 25$3.61Aug 21, 25$3.54Aug 25, 25$3.57Aug 27, 25$3.49Aug 29, 25$3.50Sep 3, 25$3.44Sep 5, 25$3.48Sep 9, 25$3.44Sep 11, 25$3.48Sep 16, 25$3.69Sep 18, 25$3.73Sep 22, 25$3.75Sep 24, 25$3.69Sep 26, 25$3.48Sep 30, 25$3.63Oct 2, 25$3.88Oct 6, 25$3.99Oct 8, 25$3.98Oct 10, 25$3.87Oct 14, 25$3.88Oct 16, 25$4.00Oct 21, 25$4.01Oct 23, 25$4.04Oct 27, 25$4.12Oct 29, 25$4.15Oct 31, 25$4.07Nov 4, 25$3.97Nov 6, 25$3.31Nov 10, 25$2.99Nov 12, 25$3.14Nov 14, 25$3.02Nov 18, 25$2.96Nov 20, 25$2.90Nov 25, 25$3.23Nov 28, 25$3.33Dec 2, 25$3.21Dec 4, 25$3.23Dec 8, 25$3.01Dec 10, 25$3.00Dec 12, 25$3.01Dec 16, 25$3.01Dec 18, 25$2.93Dec 22, 25$2.99Dec 24, 25$3.13Dec 29, 25$3.15Jan 2, 26$3.18Jan 6, 26$3.35Jan 8, 26$3.68Jan 12, 26$3.76Jan 14, 26$3.70Jan 16, 26$3.61Jan 21, 26$3.50Jan 23, 26$3.61Jan 27, 26$3.66Jan 29, 26$3.78Feb 2, 26$3.42Feb 4, 26$3.72Feb 9, 26$3.68Feb 11, 26$3.48Feb 13, 26$3.51Feb 18, 26$3.60Feb 20, 26$3.53Feb 24, 26$3.34Feb 26, 26$3.41Mar 2, 26$3.28Mar 4, 26$3.27Mar 6, 26$3.07Mar 10, 26$2.67Mar 12, 26$2.41Mar 17, 26$2.47Mar 19, 26$2.45Mar 23, 26$2.38Mar 25, 26$2.52Mar 27, 26$2.42Mar 31, 26$2.50Apr 2, 26$2.59Apr 7, 26$2.58Apr 9, 26$2.62Apr 13, 26$2.78Apr 15, 26$3.21Apr 17, 26$3.26Apr 22, 26$3.30Apr 24, 26$3.15Apr 28, 26$2.98Apr 30, 26$3.11May 4, 26$3.12May 6, 26$3.24May 8, 26$3.07May 12, 26$3.00May 14, 26$2.72May 18, 26$2.74May 20, 26$2.84May 22, 26$3.03May 28, 26$2.96Jun 1, 26$3.07Jun 3, 26$2.89Jun 5, 26$2.80Jun 9, 26$2.75Jun 11, 26$2.72Jun 15, 26$2.80Jun 17, 26$2.61Jun 22, 26$2.62Jun 24, 26$2.69Jun 26, 26$2.74Jul 2, 26$2.90
$2.3152-week range$4.26
Loading valuation history…

Fundamentals

Key fundamentals

$1.1B

Market cap

-5.0%

Revenue growth (YoY)

8.3%

Gross margin

-$78.7M

Free cash flow (USD)

-$28.7M

Net debt

Net cash position

0.5%

Share dilution

2/6

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$164.5MFY 2017$257.6MFY 2018$375.4MFY 2019$446.4MFY 2020$500.9MFY 2021$618.0MFY 2022$751.4MFY 2023$781.4MFY 2024$797.0MFY 2025$757.3M
$164.5M$757.3M

Free cash flow by year

2016 → 2025

FY 2016$57.2MFY 2017$-6.8MFY 2018$128.4MFY 2019$10.3MFY 2020$-54.4MFY 2021$3.3MFY 2022$24.5MFY 2023$-179.6MFY 2024$-114.0MFY 2025$-78.7M
$57.2M-$78.7M

Gross margin by year

2021 → 2025

FY 202124.5%FY 202223.2%FY 202322.4%FY 202414.4%FY 20258.3%
24.5%8.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingVoting Rights NotificationJun 30, 2026Filing
  • 6-K filingDirectors' DealingsJun 17, 2026Filing
  • Annual reportAnnual Report FiledMay 6, 2026Filing
  • 6-K filingBoard Nomination AnnouncementApr 30, 2026Filing
  • 6-K filingManagement ChangeApr 24, 2026Filing
  • Annual reportAnnual Report FiledApr 8, 2026Filing
  • Annual report20-F FiledApr 8, 2026Filing
  • 6-K filingManagement ChangeApr 7, 2026Filing

Questions

Frequently asked questions

What is Evotec SE's market cap?

Evotec SE (EVO) has a market capitalization of $1.1B.

What is EVO's P/E ratio?

A meaningful P/E ratio is not available for EVO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying EVO stock?

SEC Form 4 filings show no open-market insider buys at Evotec SE in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

COLL

Collegium Pharmaceutical, Inc.

$1.1B

ALVO

Alvotech

$1.1B

CRON

Cronos Group Inc.

$1.1B

PCRX

Pacira BioSciences, Inc.

$925.6M

PAHC

Phibro Animal Health Corporation

$1.3B

HROW

Harrow Health, Inc.

$1.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.